10-Q quarterly report · filed Nov 5, 2026

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Q3 2026 10-Q Quarterly Report

Short answer

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $121M (up 80.1% year over year) with net income of −$22M.

Q3 2026 key financials · XBRL

Revenue
$121M
+80.1% YoY · +22.3% QoQ
Net income
−$22M
+75.6% YoY · +52.9% QoQ
Operating margin
-19.7%
EPS (diluted)
−$0.05
+80.0% YoY · +50.0% QoQ

Source: XBRL data from the IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Q3 2026 10-Q on SEC EDGAR. USD.

IOVANCE BIOTHERAPEUTICS, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $121.5M, up 80% YoY from $67.5M, driven by Amtagvi $101.6M versus $57.5M
  • Proleukin revenue $19.9M, up from $10.0M YoY, the fastest product growth at 99%
  • Net loss $22.3M versus $91.3M YoY, with total costs and expenses $145.4M versus $162.4M
  • Cash, equivalents, investments and restricted cash $382.3M, including $318.4M in short-term investments
  • Operating cash outflow $137.4M for nine months, with $87.9M quarterly net proceeds from stock sales

Risk Factors

  • New UPS/DDLPS registrational trial commenced in Q2 2026, increasing clinical execution and regulatory approval risk
  • Manufacturing centralized at iCTC after Minaris exit in January 2026, creating near-term capacity and supply continuity risk
  • FDA accelerated approval for Amtagvi requires confirmatory TILVANCE-301 Phase 3 trial, with failure threatening full approval
  • Cash resources $382.3 million versus $148.6 million net loss for nine months ended September 30, 2026
  • OBBBA changes may reduce ACA Marketplace and Medicaid coverage, potentially constraining reimbursement and product access

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other IOVANCE BIOTHERAPEUTICS, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.